Vumedi Announces $104M Series B for AI-Powered Physician Learning Platform
Vumedi, a peer-to-peer video learning platform for physicians, has received a $104 million Series B growth investment from Oak HC/FT. The company announced the funding on November 10, 2026, in a press release.1
By Victoria Shi · AI Funding Reporter Nov 18, 2026

The company provides an on-demand clinical resource with a library of more than 100,000 physician-led videos and nearly 5,000 podcast episodes across more than 21 specialties, according to the announcement and a social media post from Oak HC/FT. Vumedi said its artificial intelligence tools process this library to connect clinical questions with specialist experience.

Team · Where leadership came from
Vumedi's six leaders came from 14 different companies
6 of 15 VP-and-up leaders have earlier employers on record · 14 distinct companies, most-shared first
Cornerstone OnDemandVice President, Customer Success
DialpadChief Financial Officer
AncestryChief People Officer
Pfizer IncChief Executive Officer, Board Director | Life Science Innovation, Development, & Commercialization | Biotechnology | Medical Device | Entrepreneurship | Capital Formation
Everyday HealthChief Commercial Strategy Officer
BoxChief People Officer
Practice Fusion from VeradigmChief Commercial Strategy Officer
Nok Nok (Now OneSpan)Chief Financial Officer
Hewlett Packard EnterpriseChief People Officer
Saba Software, IncChief Financial Officer
GoogleChief People Officer
McMahon GroupChief Commercial Strategy Officer
NBCUniversalCEO and Founder- Us Surgical CorporationChief Executive Officer, Board Director | Life Science Innovation, Development, & Commercialization | Biotechnology | Medical Device | Entrepreneurship | Capital Formation
Earlier employers from LinkedIn work history, leader titles only · board seats and self-employment left out · a company counts once per leader · frozen 2026-11-18
Where leadership came from, 1 of 3
3 charts on Vumedi · 1 of 3
According to the company, the Series B capital has been used for investment in talent, research and development, product development, and outreach. Vumedi stated it will continue to invest in AI and product development to improve the searchability and accessibility of its content.1
“That makes access to real clinical experience more important,” said Roman Giverts, founder and CEO of Vumedi, in the press release.
The company, founded in 2008, reported that its AI tools have been used by over 150,000 clinicians and generated more than 1 million interactions in less than a year. The announcement also stated that users of its AI tools spend 3.5 times more time on the platform compared to non-AI users, and that users have watched over 56 million minutes of educational content in the past year.